Literature DB >> 2551735

Human gelatinase/type IV procollagenase is a regular plasma component.

T Vartio1, M Baumann.   

Abstract

Gelatin zymograms revealed in human plasma a constant 66 kDa proteolytically active polypeptide. In most plasma samples other major proteolytic activities were seen at Mr 92,000, 130,000 and 225,000. All four proteases were Ca2+-dependent metalloproteases and bound quantitatively to gelatin-Sepharose. Immunoblotting results indicated that the 66 kDa protease was the human fibroblast gelatinase/type IV procollagenase and that the other three proteases were macrophage/granulocyte-derived gelatinase components. The 66 kDa protease did not bind to conA- nor lentil lectin-Sepharose allowing its separation from the 92, 130 and 225 kDa proteases. During the isolation procedure the plasma gelatinase/type IV procollagenase tended to form a proteolytically active spontaneous disulfide-bonded dimer and a 62 kDa component that could also be obtained by digestion with trypsin. The same polypeptide changes occurred also in stored preparations of the corresponding protease isolated from fibroblast culture medium while the freshly purified protein contained only the 66 kDa proform.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551735     DOI: 10.1016/0014-5793(89)81107-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.

Authors:  Juanjuan Chen; Zongli Ren; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-05-12       Impact factor: 5.858

2.  Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway.

Authors:  G S Makowski; M L Ramsby
Journal:  Inflammation       Date:  1998-06       Impact factor: 4.092

3.  Amorphous calcium phosphate-mediated binding of matrix metalloproteinase-9 to fibrin is inhibited by pyrophosphate and bisphosphonate.

Authors:  G S Makowski; M L Ramsby
Journal:  Inflammation       Date:  1999-08       Impact factor: 4.092

4.  Binding of matrix metalloproteinase 9 to fibrin is mediated by amorphous calcium-phosphate.

Authors:  G S Makowski; M L Ramsby
Journal:  Inflammation       Date:  1998-12       Impact factor: 4.092

5.  Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.

Authors:  Roopali Roy; Gwendolyn Louis; Kevin R Loughlin; Dmitri Wiederschain; Susan M Kilroy; Carolyn C Lamb; David Zurakowski; Marsha A Moses
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

6.  Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus.

Authors:  G S Makowski; M L Ramsby
Journal:  Mol Pathol       Date:  2003-08

7.  Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases.

Authors:  I Sopata; J Wize; A Filipowicz-Sosnowska; E Stanisławska-Biernat; B Brzezińska; S Maśliński
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 8.  Hemostasis and alterations of the central nervous system.

Authors:  Gregory J del Zoppo; Yoshikane Izawa; Brian T Hawkins
Journal:  Semin Thromb Hemost       Date:  2013-10-28       Impact factor: 4.180

9.  Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity.

Authors:  M J Arthur; A Stanley; J P Iredale; J A Rafferty; R M Hembry; S L Friedman
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

10.  Walker 256 cancer cells secrete tissue inhibitor of metalloproteinase-free metalloproteinase-9.

Authors:  Maria Pavlaki; Eleftheria Giannopoulou; Anna Niarakis; Panagiota Ravazoula; Alexios J Aletras
Journal:  Mol Cell Biochem       Date:  2009-03-29       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.